Contrasting open surgery, MIS lets doctors to operate with less impairment to the body, causing a lesser amount of pain, less complications, and shorter hospital stay for patients. For instance, laparoscopy, one of the better-known minimally invasive surgery, usages small incisions to pass small tubes, cameras and devices so doctors can work without a conventional surgical method.

Another this kind of surgery is robotic surgery, in which medics can make numerous complex procedures with added accuracy, suppleness, and control because they are assisted by a robot that improves their competences and helps them overcome numerous limitations of surgical procedures.

Defining Robotic Surgery

Robotic surgery is an advanced surgery using robots to do what people can’t. Considering how bulky human hands are as opposed to robotic arms, which can be thinner while retaining a high dexterity allowing manoeuvring in tight places in the body. Additionally, when you present automatic elements paired with feedback-controlled surgery motions, you get much smoother actions than human hands. This gives surgeons more control on surgeries while also plummeting tissue trauma.

How Does Robotic Surgery Work? While there are numerous robotic surgery procedures, the enormous majority will include a surgeon sitting at a distinct console with controls at foot and hand allowing remotely and exactly control surgical tools attached to robotic arms. Alterations can also be done to alter the scale of the robot’s movement.

Instruments Used in Robotic Surgery Usually, robotic surgery is done with the da Vinci Surgical System, having FDA approval for use in surgeries including: ● Cardiac: Where apt, minimally invasive procedure is done and not open heart surgery. ● Colorectal: Colon and rectal resection surgery, along with rectopexy can be done with the help of robot. ● General surgery: General surgery comprises numerous procedures like inguinal hernia repair that can be done with the help of robots. ● Gynecology: Doctors may suggest robotic benign hysterectomy. ● Head and neck: Transoral robotic surgery might be an alternative for mouth and throat surgery. ● Thoracic: When surgery for lung cancer is to be done, doctors might choose robotic surgery. ● Urology: Doctors might advise robotic surgery for urology procedures for kidney or prostate.

Compensations of Robotic Surgery There are several advantages of robotic surgeries. For instance, the fact that operation is done through a small incision implies that there is less pain along with negligeable scarring, briefer hospitalization, and faster recovery. The use of HD 3D cameras gives improved visualization as surgeons gain close-up of areas not accessible in conventional surgery. Similarly, the use of robotic arms mimicking the movement of hands offer surgeons with improved deftness and greater accuracy than could ever be possible with conformist surgical instruments.

Medical Electrodes Market Expected to Witness Considerable Growth in Coming Years

With the rising volume of minimally invasive procedures, booming geriatric population, and increasing prevalence of lifestyle-associated and chronic diseases, the usage of medical electrodes is surging. As a result, the global medical electrodes market is predicted to grow at a 6.7% CAGR between 2021 and 2025 (forecast period), to reach $1,151.6 million by 2025. During the first quarter of 2020, the lockdowns and movement restrictions imposed in the wake of the COVID-19 pandemic affected the medical electrodes market negatively, as the production and trade of such products came to a standstill. However, as the manufacturing sector began rebounding in the second quarter, the supply of medical electrodes to an already stressed healthcare sector resumed, which will now continue pushing up the market value in the coming years. Demand for Disposable Electrodes To Rise Faster Reusable and disposable are the bifurcations of the medical electrodes market when it is segmented based on usability. Of these, the higher CAGR during the forecast period will be seen in the disposable bifurcation, as disposable electrodes are easy to use and cost-effective, do not need to be sterilized, and carry a minimal risk of hospital-acquired infections (HAI). On segmenting the market on the basis of modality, the categories are electroencephalography (EEG) & brainstem auditory evoked potential (BAEP), electrocardiography (ECG), electromyography (EMG), and others. Among these, the ECG category dominated the medical electrodes market in 2020 due to the already high prevalence of cardiovascular disorders, including coronary artery disease, arrhythmias, and atherosclerosis, which continues to surge. An ECG maps the flow of electrical current through the heart muscle, to give an idea of the heart rhythm in the form of a graph. Additionally, this test vaguely informs doctors of the blood flow into, within, and out of the heart. Since both these parameters are important in diagnosing a range of chronic diseases, the healthcare sector conducts a high volume of ECGs every day; hence, the demand for the associated electrodes is quite high. During the forecast period, Asia-Pacific (APAC) is projected to be the fastest-growing medical electrodes market, on account of its large population of the elderly, increasing spending on healthcare, and rising incidence of chronic diseases.

The rising incidence of autoimmune diseases, growing geriatric population, advent of novel biomarkers, increasing initiatives being taken by various government and private organizations for raising public awareness about autoimmune diseases, and the soaring strategic development projects and activities being launched by the market players are the key factors fueling the expansion of the global autoimmune disease diagnostics market. Furthermore, the market is predicted to attain a valuation of $10,012.9 million in 2030, exhibiting a CAGR of 8.5% from 2020 to 2030. Based on product, the autoimmune disease diagnostics market is categorized into instruments and consumables and assay kits. Of these, the consumables and assay kits category is predicted to dominate the market in the future years, on account of the growing incidence of autoimmune diseases and the rising requirement for tests, such as enzyme-linked immunosorbent assay (ELISA), rheumatoid factor (RF) & anti-cyclic citrullinated peptide (CCP) antibody, and antinuclear antibody (ANA) immunofluorescence assay (IFA).

Globally, the North American autoimmune disease diagnostics market is predicted to exhibit lucrative growth in the upcoming years, owing to the rapid improvements in healthcare facilities and infrastructure, growing prevalence of autoimmune diseases, rising research activities, soaring geriatric population, and the existence of several leading market players in the region. The players operating in the global autoimmune disease diagnostics market are increasingly focusing on developing and commercializing products for enhancing their market position. For example, F. Hoffmann-La Roche Ltd. announced in September 2019 that it had received approval from the USFDA (United States Food and Drug Administration) for the usage of the cobas Babesia test on the cobas 6800/8800 systems. This test would be used for testing the blood donated by individuals and it follows the May 2019 updated guidelines of the FDA which recommend the screening and testing of donated blood for Babesia for reducing the chances of the transmission of the parasite through transfusions.

E-clinical solutions are used by healthcare providers, contract research organizations (CROs), and pharmaceutical and biotechnology companies, to acquire, manage, convert, and standardize data. Owing to such features, e-clinical solutions are widely used for clinical trials conducted by pharmaceutical and biotechnology companies. Furthermore, the CROs are using such solutions for supporting the pharmaceutical and medical device sectors, by offering research services, such as biopharmaceutical development, clinical trials management, preclinical research, clinical research, and biological assay management, on a contractual basis.

Adoption of e-clinical solutions has accelerated, due to rising attempts to invent treatments for diseases like cancer, acquired immunodeficiency syndrome (AIDS), and diabetes. These attempts have encouraged pharmaceutical, biopharmaceutical, clinical research, and life sciences firms to invest hefty amounts in the development of e-clinical solutions market. Furthermore, surging incidence of cancer and diabetes will increase the application of e-clinical solutions. For example, the World Health Organization (WHO) states that cancer accounts for nearly 9.6 million deaths, annually. Whereas, the International Diabetes Federation (IDF) estimates that around 629 million people will suffer with diabetes, globally, by 2045. Additionally, booming ageing population will accelerate the requirement of e-clinical solutions, as the elderly are highly susceptible to chronic diseases like cancer, diabetes, and cardiovascular diseases (CVDs). According to the United Nations Department of Economic and Social Affairs (UNDSEA), the population size of individuals aged 65 years or above will reach 225.4 million in India, 356.6 million in China, 84.8 million in the U.S., and 52.0 million in Brazil, by 2050. They require better drugs due to the rising complexities in life-threatening diseases, on account of climatic abnormalities and changing lifestyle pattern. Another factor driving the demand for such solutions is the government efforts to digitally transform their medical infrastructure. For instance, as part of its Health Information Technology for Economic and Clinical Health (HITECH) Act, the U.S. government incentivizes healthcare professionals who use digital technologies. Similarly, in 2015, the European Union (EU) announced plans to invest $18.1 million for developing the digital health infrastructure in the region, so that as many medical services as possible can be dispensed virtually, thereby resulting in time and cost savings for patients as well as caregivers. According to P&S Intelligence, North America dominates the e-clinical solutions market, due to the surging expenditure on research and development (R&D) by pharmaceutical and biotechnology companies. Whereas, the Asia-Pacific (APAC) market will exhibit the fastest growth in coming years, on account of growth in clinical trial outsourcing in emerging economies like India and China. Clinical trials in these countries are escalating, owing to cost-efficiency and availability of a large number of patients in these nations. Pharmaceutical companies in APAC are constantly focusing on clinical trials, thereby, amplifying the application of e-clinical solutions. With the high penetration of chronic diseases and the vast population size of the elderly, coupled with rising number of R&D activities by pharmaceutical and biotechnology companies, the adoption of e-clinical solutions will escalate, globally.

Rising Diabetes Cases Driving Surgical Sutures Demand in Saudi Arabia

The U.S. Centers for Disease Control and Prevention (CDC) states that stroke, cirrhosis, diabetes, ischemic heart disease, chronic kidney disease, lower respiratory infections, and neonatal disorders are the leading causes of death in Saudi Arabia. According to the Ministry of Health, under the Kingdom of Saudi Arabia, diabetes is one of the most prevalent diseases in the country. As per the Ministry, diabetes causes cardiovascular diseases (CVDs), nerve damage, kidney damage, eye damage, cancer, and Alzheimer's disease among the affected population.

Moreover, the soaring number of hospitals and healthcare professionals will also augment the need for surgical sutures in the country in the upcoming years. As per the Ministry of Health, there were 89,093 nurses, 41,201 physicians, and 78,596 hospitals in Saudi Arabia in 2020. These hospitals and healthcare professionals use absorbable and non-absorbable sutures and reusable and disposable automated suturing devices while performing surgical procedures on patients, which, in turn, drive the demand for surgical sutures in the country. At present, companies operating in the Saudi Arabian surgical sutures market are focusing on mergers and acquisitions to offer improved products that can be used in general surgeries, orthopedic surgeries, gynecological surgeries, CVD surgeries, and ophthalmic surgeries. For instance, in January 2016, Surgical Specialties Corporation acquired all the affiliated entities and shares of FSSB Chirurgische Nadeln GmbH, a suture and needle manufacturing company, for $147 million. Through this acquisition, the former aims to expand its needle business by using the proprietary technology of the latter. Thus, the rising cases of chronic diseases and burn injuries and the increasing number of hospitals and healthcare professionals will create a huge requirement for surgical sutures in Saudi Arabia in the foreseeable future.

Surgical, Face, and Respiratory Mask Market To Generate $15,696.2 Million Revenue by 2030 A number of factors, such as the soaring air pollution levels, surging volumes of surgeries, booming geriatric population, and increasing prevalence of airborne diseases, will drive the surgical, face, and respiratory mask market at a CAGR of 5.7% during the forecast period (2020–2030). According to P&S Intelligence, the market generated a revenue of $2,141.3 million in 2019 and it is projected to reach $15,696.2 million by 2030. Moreover, the COVID-19 outbreak has also facilitated the market growth, worldwide.

The rising air pollution level is one of the prominent growth drivers for the market. Rapid industrialization and urbanization have led to the emission of a large volume of pollutants in the atmosphere. The increasing number of vehicles and manufacturing units, on account of urbanization and industrialization, are harming the air quality in numerous ways. The soaring air pollution level is resulting in lung cancer, respiratory infections, chronic lung diseases, and heart diseases and strokes. To avoid falling prey to these ailments, people are using surgical, face, and respiratory masks in abundance. The product type segment of the surgical, face, and respiratory mask market is divided into surgical and respiratory. Of these, the respiratory category is expected to account for larger market share in the forecast years, owing to the high air pollution levels and high prices of respiratory masks. Whereas, the surgical category will demonstrate faster growth in the coming years, due to the surging incidence of airborne diseases and increasing volume of surgeries. Moreover, the COVID-19 pandemic has augmented the sale of surgical masks, as these help in minimizing the spread of the virus. Geographically, Asia-Pacific (APAC) held the largest share in the surgical, face, and respiratory mask market in 2019, and it is projected to retain its dominance in the coming years as well. This can be attributed to high air pollution levels and increasing prevalence of airborne diseases, which compel people to wear masks, while commuting or going out. Moreover, the rampant spread of coronavirus in APAC countries has also fueled the demand for such masks. Besides, increasing number of hospitals and healthcare professionals have also supported the growth of the regional market. Thus, the rapid spread of coronavirus and the high air pollution levels will augment the demand for surgical, face, and respiratory masks in the forecast years, across the world. Read the full report - Surgical, Face and Respiratory Mask Market Insight

Booming Geriatric Population Supporting Disposable Plastic Blood Bag Market Moreover, the market value is predicted to shoot up in the forthcoming years, mainly because of the rising incidence of chronic illnesses and soaring population of geriatric people across the world. In addition, the launch of several initiatives by the governments of many countries for raising awareness about blood donations and the advantages of using disposable plastic blood bags is also predicted to support the expansion of the market in the upcoming years.

According to the World Population Ageing 2020 report published by the United Nations Department of Economic and Social Affairs (UNDESA), the population of people aged 65 years or above will grow from 727 million in 2020 to more than 1.5 billion by 2050. Since old people are vulnerable to various chronic ailments, their ballooning population is contributing heavily toward the surging need for disposable plastic blood bags. Additionally, the increasing concerns being raised over the deteriorating environment are also fueling the sales of disposable plastic blood bags across the world. The disposable plastic blood bag market is classified into quadruple, triple, double, and single categories. Out of these, the single category is predicted to hold the largest share in the market in the coming years. The market is also divided, depending on end user, into home healthcare, hospitals, and blood banks. Amongst these, the hospitals category is predicted to contribute the highest revenue to the market in the forthcoming years. Furthermore, this category is also expected to demonstrate the fastest growth in the upcoming years. Across the globe, North America is currently holding the largest share in the disposable plastic blood bag market. This is attributed to the growing prevalence of blood disorders and the soaring investments being made in research and development (R&D) projects by several market players in the region. For instance, chronic and acute myeloid leukemia are the most prevalent types of leukemia in the region. According to the findings of the Leukemia and Lymphoma Society in the U.S., one person is diagnosed with blood cancer in the U.S. every three minutes. As per the estimates of the market research firm, P&S Intelligence, the U.S. will dominate the regional market in the coming years. Thus, it can be safely said that the demand for disposable plastic blood bags will surge sharply in the coming years, primarily because of the growing prevalence of chronic diseases, mushrooming population of geriatric people, and surging concerns being raised over the escalating pollution levels all over the world.

Prefilled Syringes Market Set for Rapid Expansion in Future The global prefilled syringes market attained a value of $1,914.1 million in 2020, and it is predicted to progress at a CAGR of 6.8% between 2021 and 2030. Furthermore, the market is predicted to reach a revenue of $3,646.7 million by 2030. The factors fueling the expansion of the market are the surging concerns raised over the prevalence of needlestick injuries, various advantages of prefilled syringes over conventional vial and syringe packaging systems, and the burgeoning requirement for point-of-care administration.

Additionally, the growing incidence of lifestyle-associated and chronic diseases and the soaring requirement for injectable pharmaceutical products are fueling the expansion of the market. Vaccines and therapeutic agents are some of the major injectable pharmaceutical products that are experiencing a surge in demand. As per the World Health Organization (WHO), nearly 16 billion injections, including 95% for curative care, 2% for contraceptives and blood transfusion procedures, and 3% for immunization are administered across the world every year. This was because of their ability to prevent reactions between the syringe surface and different drug molecules. However, in the forthcoming years, the plastic-based category is predicted to demonstrate higher growth rate in the market. This will be because of the usage of advanced polymers such as crystal-clear polymer, that are biocompatible with various components of prefilled syringes, and polypropylene for their production. The market is also classified, on the basis of application, into diabetes, anaphylaxis, cancer, and rheumatoid arthritis. Out of these, the diabetes category held the largest share in the market in 2020, and it is predicted to retain its dominance in the upcoming years as well. Diabetes affects the production of insulin and the ability of the cells to respond appropriately to the insulin produced by the pancreas, which, in turn, disbalances the blood glucose level in the body. Thus, to meet this insulin requirement, diabetics need supplemental insulin, which is primarily taken through syringes. Globally, Europe contributed the highest revenue to the prefilled syringes market in 2020, because of the high incidence of non-communicable diseases such as cancer, cardiovascular diseases, and diabetes in the region. In the future years, the market will demonstrate the fastest growth in Asia-Pacific (APAC), as per the estimates of the market research company, P&S Intelligence. This will be because of the surging healthcare expenditure in the major Asian countries and the growing incidence of chronic diseases in the region. Therefore, it can be said without any hesitation that the market will boom in the forthcoming years, mainly because of the growing incidence of various non-communicable, chronic, and lifestyle-associated diseases, burgeoning requirement for injectable pharmaceutical products, and the surging geriatric population all over the world.

Why Coming Years Are Vastly Lucrative for Vial Manufacturers? Parenteral (via injection) is one of the most-effective ways of administering any therapeutic or diagnostic agent into the human body as it takes the agent faster into the bloodstream compared to oral, nasal, and others, such as skin patches. Moreover, ever since the invention of the vaccine by Edward Jenner in 1796, the parenteral route of drug administration has been greatly advanced and simplified. One of the key objects required for vaccination is the vial, a glass or plastic container that stores the agent to be injected. Hence, with the rising popularity of injectable drugs, P&S Intelligence forecasts an 8.6% CAGR for the vials market during 2021–2030. At this rate, the revenue generated by their manufacturers will rise from $1,263.0 million in 2020 to $3,047.0 million by 2030. These products are widely used by medical research institutions, pharmaceutical and biotechnology companies, and healthcare settings, such as hospitals, clinics, and diagnostic centers. Among these, pharma and biotech companies have been the largest users of vials till now because they need these products in high volumes for storing and transporting vaccines and other injectable agents.

Moreover, even before the pandemic, the demand for these containers had been increasing steadily with the consistent growth in the pharmaceutical and biotech sectors. This was because of the rising prevalence of all kinds of chronic and acute diseases, such as influenza, Zika, Ebola, cardiovascular diseases (CVDs), cancer, diabetes, and chronic obstructive respiratory disease (COPD). For instance, most diabetics require daily shots of insulin, which is often sourced from a vial. Similarly, in case of severe anaphylaxis, patients require immediate epinephrine (adrenaline) injections. Due to these reasons, Europe has been the largest vials market till now, and it will continue being so in the years to come. The region is home to numerous vial manufacturers, such as Schott AG, Stevanato Group, Gerresheimer AG, and SGD S.A. Moreover, some of the largest pharma companies in the world, including GlaxoSmithKline plc, Sanofi S.A., F. Hoffmann-La Roche AG, AstraZeneca, Novartis International AG, Bayer AG, and Merck KGaA, are based in Europe. Moreover, here, healthcare is easily accessible to the masses, primarily through government schemes. Hence, with the growing pharmaceutical and biotechnology industry, the demand for vials will rise.

The North American patient engagement solutions market growth thrives on the surging use of mobile health solutions, increasing implementation of value-based systems by healthcare providers to reduce their burden, rising number of government initiatives promoting patient-centric care, mounting burden of chronic diseases, and booming aging population in the U.S. and Canada. Additionally, the implementation of stringent government regulations on patient-centric care and the widescale adoption of cloud-based systems in the healthcare sector will also drive the demand for patient engagement solutions in the region. The expanding population base of old people in Canada and the U.S. will drive the demand for patient engagement solutions in North America. The surging use of such technologically advanced healthcare and medical solutions helps the elderly population stay connected with their healthcare providers, as they are sometimes unable to travel for treatment. According to Statistics Canada, nearly 18.5% of the Canadian population was aged 65 years and above in 2021. Moreover, as per the U.S. Census Bureau, the number of people aged 65 years and older in the U.S. in 2019 was 54.1 million. Presently, the patient engagement solutions industry in North America is consolidated, due to the presence of a few key players such as athenahealth Inc., Allscripts Healthcare Solutions Inc., Cerner Corporation, International Business Machines Corporation (IBM), Lincor Inc., and McKesson Corporation. In recent years, the market players have actively engaged in mergers and acquisitions to consolidate their position. For example, in June 2017, athenahealth Inc. acquired Praxify Technologies Inc. to facilitate its R&D initiatives by integrating technologies of the latter into the cloud platform of the former.